Building America's first trusted peptides brand
What these compounds are, what the research actually shows, and exactly where each one stands with U.S. regulators - every claim linked to a source you can check. When the public comment window opens, you'll be first to know.
Educational resource only. Not medical advice. Not affiliated with the U.S. Food and Drug Administration.
Start here
What the July 2026 FDA review is — and the public comment window that actually decides access.
What we do
Peptides are everywhere in the conversation and almost nowhere in plain English. The gap fills with hype from sellers and hand-waving from skeptics - and very little you can actually check. Peppies lives in that gap: one place that explains the science straight and links every claim to a primary source.
We'll be straight about ourselves, too. Peppies is a company, not a nonprofit. We're building toward being the peptides brand America trusts, and we'll offer products the day the science and the law allow - not a day before. We don't sell peptides today, and won't until it's legal to. Until then, our job is simple: be the clearest, most honest voice in the room.
The Peptide Library
All seven peptides on the July 2026 FDA advisory agenda, each with its own cited profile: what it is, what the research shows, and where it stands with regulators.
Day 1 · Peptide profile
The one everyone's talking about - in animal studies it helped heal tendon, gut, and muscle alike. FDA-evaluated for ulcerative colitis.
Under reviewDay 1 · Peptide profile
Tiny but mighty: a 3-building-block fragment studied for calming inflammation without steroids. FDA-evaluated for wound healing.
Under reviewDay 1 · Peptide profile
The recovery world's favorite, built from a natural tissue-repair protein. FDA-evaluated for wound healing.
Under reviewDay 1 · Peptide profile
“Exercise in a molecule” - a mitochondrial signal studied for metabolism, weight, and bone. FDA-evaluated for obesity and osteoporosis.
Under reviewDay 2 · Peptide profile
The “deep-sleep” peptide, first found in sleeping animals. FDA-evaluated for insomnia, narcolepsy, and withdrawal.
Under reviewDay 2 · Peptide profile
Prescribed in Russia for decades for the brain - studied for focus and stroke recovery. FDA-evaluated for cerebral ischemia and migraine.
Under reviewDay 2 · Peptide profile
A longevity favorite, studied for switching telomerase back on. FDA-evaluated for insomnia.
Under reviewThe full picture
The timeline, the advisory vote, and the comment window that actually decides access.
Next Up - The later-review cohort
The FDA pulled twelve peptides off the "do not compound" list in April 2026. Seven go before the committee in July; these five weren't scheduled for that meeting and are expected to be taken up in a later review (reported as early 2027). Same cited treatment, so you're ready when they come up.
Later review · Profile
Your body's own antibiotic - a natural germ-fighter studied against resistant bugs and for wound healing.
Later reviewLater review · Profile
Startling on paper: reported to build brain connections and reverse memory loss in mice. No human trials yet.
Later reviewLater review · Profile
The copper peptide beloved in high-end skincare for collagen and repair; the injectable form is under review.
Later reviewLater review · Profile
Targets the muscle's own repair switch - studied for recovery and growth in animal models.
Later reviewLater review · Profile
The “tanning” peptide - and the one to be careful with: linked to real harms and FDA warnings.
Later reviewThe Regulatory Center
The plain-English read on the FDA review — and the moment that actually decides access.
In September 2023, the FDA put a group of peptides - BPC-157 among them - into "Category 2" of its interim list of bulk substances for pharmacy compounding, the bucket for substances that raise significant safety questions. In April 2026, the agency pulled twelve of them back out and called an advisory committee to take a fresh look.
On July 23-24, 2026, that committee hears the evidence on seven peptides and votes a recommendation. The vote is advisory, not final - and in its own briefing materials, FDA staff have proposed not adding any of the seven to the approved list. What happens next runs through formal rulemaking, the stage where the public comment actually carries legal weight.
That comment window is the moment that counts. We're watching for it so you don't have to.
Track it at the source: FDA meeting page · Federal Register notice · Regulations.gov (docket FDA-2025-N-6895).
Get notified
Join the list and we'll send you plain-English updates on the review - and a heads-up the moment the official public comment window opens, with step-by-step instructions to submit your own.
PEPPIES
now
No spam. Unsubscribe anytime. We never sell your information.
xxxx people are already following the review.
By submitting, you agree to our Privacy Policy and Terms. Your consent and a timestamp are recorded for compliance.
Explore by interest
Peptides come up in very different conversations. Start wherever you are - we'll give you the exciting research and the honest caveats, side by side.
The peptides that dominate gym, recovery, and longevity talk - BPC-157, TB-500, MOTS-c, PEG-MGF. What the research actually shows, and what it doesn't.
Explore this path →The peptides behind the skincare and anti-aging buzz - GHK-Cu, Epitalon, KPV, and more. We separate the real science from the marketing.
Explore this path →The Peppies shop
Slow and steady wins the race. Our merch helps fund independent peptide education - apparel and gear featuring the Peppies mark are on the way.
Visit the shopCommon questions
Everything in one place
The whole hub — the peptides, the regulatory fight, the evidence, and the resources for reporters — in plain English and cited throughout.